JoVE Logo
Faculty Resource Center

Sign In

Summary

Abstract

Introduction

Protocol

Representative Results

Discussion

Acknowledgements

Materials

References

Cancer Research

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published: September 25th, 2018

DOI:

10.3791/58082

1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Hospital University Federation OncoAge, Université Côte d’Azur, 2Institute for Research on Cancer and Aging in Nice (Inserm U1081 and CNRS 7284), Université Côte d’Azur, 3Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d’Azur

To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.

Pembrolizumab monotherapy has been approved for the first- and second-line treatment of patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC). Testing for PD-L1 expression with the PD-L1 immunohistochemistry (IHC) 22C3 companion diagnostic assay, which gives a tumor proportion score (TPS), has been validated on tumor tissue. We developed an optimized laboratory-developed test (LDT) that uses the 22C3 antibody (Ab) concentrate on a widely available IHC autostainer for biopsy and cytology specimens. The PD-L1 TPS was evaluated with 120 paired whole-tumor tissue sections and biopsy samples and with 70 paired biopsy and cytology samples (bronchial washes, n = 40; pleural effusions, n = 30). The 22C3 Ab concentrate-based LDT showed a high concordance rate between biopsy (~100%) and cytology (~95%) specimens when compared to PD-L1 IHC expression determined using the PD-L1 IHC 22C3 companion assay at both TPS cut points (≥1%, ≥50%). The optimized LDT presented here, using the 22C3 Ab concentrate to determine the PD-L1 expression in both tumor tissue and in cytology specimens, will expand the ability of laboratories worldwide to assess the eligibility of patients with NSCLC for treatment with pembrolizumab monotherapy in a reliable and reproducible manner.

Recent clinical trials have demonstrated the efficacy of pembrolizumab, a humanized monoclonal IgG4 kappa isotype antibody that blocks the interaction between programmed cell death 1 (PD-1) and its ligands, PD-L1 and PD-L2, in the treatment of patients with advanced NSCLC1,2,3,4.

Currently, pembrolizumab is approved for treatment of PD-L1-expressing NSCLC in both treatment-naive patients with a PD-L1 expression TPS of ≥50% and no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gen....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

All procedures have been approved by the local ethics committee (Human Research Ethics Committee, Centre Hospitalier Universitaire de Nice/Tumorothèque BB-0033-00025).

NOTE: This protocol is specifically adjusted for the use of the 22C3 antibody concentrate on a commercially available automated IHC stainer (referred to as autostainer here, see the Table of Materials) for tumor biopsies and cytology samples.

1. Preparation of Tumor Tissue Samples<.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Using the procedure presented here, and as described in detail in this group's recent publications10,11, the optimized LDT was clinically validated with 120 archival FFPE NSCLC biopsy samples from patients who underwent surgical resection or a biopsy at the Pasteur University Hospital, Nice, between March 2007 and March 2016. Moreover, for the evaluation of PD-L1 expression of cytology samples, TPS was evaluated in 70 paired t.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

We have validated an optimized LDT using the 22C3 PD-L1 antibody concentrate, by comparing it with the corresponding clinically validated commercial test10,11. The 22C3 concentrated antibody-based LDT showed a high concordance rate between biopsy (~100%) and cytology (~95%) specimens when compared to the PD-L1 IHC expression determined using the PD-L1 IHC 22C3 assay at both ≥1% TPS and the ≥50% TPS cut points. As recently recommended by the Internatio.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

This study was sponsored by Merck & Co., Inc., Kenilworth, NJ, USA. The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Name Company Catalog Number Comments
NovaPrep HQ1 Novacyt NA Preservative solution for cytology specimens
Novaprep® HQ+ B Novacyt NA Mucolytic solution
Tissue-Tek VIP 6 Sakura 6042 VIP 6
Tissue-Tek TEC 5 Tissue Embedding Console System Sakura 5229 TEC 5
microscope glass slide SuperFrost Plus Thermo Fisher Scientific 4951PLUS4
DL-Dithiothreitol powder Sigma-Aldrich D3801
Heidolph Multi Reax Vortex Shaker Thermo Fisher Scientific 13-889-410
Shandon Cytoblock Thermo Fisher Scientific 7401150
22C3 anti-PD-L1 concentrate antibody Agilent Dako #M365329
PD-L1 IHC 22C3 pharmDx Agilent Dako SK006
Autostainer Link 48 Agilent Dako AS480
BenchMark ULTRA autostainer Ventana #750-600
OptiView HQ Universal Linker Ventana #760-700
OptiView HRP Multimer Ventana #760-700
OptiView Amplification H2O2 Ventana #760-099
OptiView Amplifier Ventana #760-099
OptiView Amplification Multimer Ventana #760-100
OptiView DAB Ventana #760-700
OptiView Copper Ventana #760-700
Hematoxylin II Ventana #790-2208
Bluing Reagent Ventana #760-2037
Cell Conditioning 1 (CC1) Ventana #950-124
Tissue-Tek Film Coverslipper Sakura 4742

  1. Garon, E. B., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine. 372 (21), 2018-2028 (2015).
  2. Herbst, R. S., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 387 (10027), 1540-1550 (2016).
  3. Reck, M., et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine. 375 (19), 1823-1833 (2016).
  4. Langer, C. J., et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 17 (11), 1497-1508 (2016).
  5. Buttner, R., et al. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 35 (34), 3867-3876 (2017).
  6. Folch, E., Costa, D. B., Wright, J., VanderLaan, P. A. Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Translational Lung Cancer Research. 4 (4), 392-403 (2015).
  7. Padmanabhan, V., et al. Improving Adequacy of Small Biopsy and Fine-Needle Aspiration Specimens for Molecular Testing by Next-Generation Sequencing in Patients With Lung Cancer: A Quality Improvement Study at Dartmouth-Hitchcock Medical Center. Archives of Pathology & Laboratory Medicine. 141 (3), 402-409 (2017).
  8. Tsao, M. S., et al. . IASLC ATLAS of PD-L1 Immunohistochemistry Testing in Lung Cancer. , (2017).
  9. Thunnissen, E., de Langen, A. J., Smit, E. F. PD-L1 IHC in NSCLC with a global and methodological perspective. Lung Cancer. , 102-105 (2017).
  10. Ilie, M., et al. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS One. 12 (8), e0183023 (2017).
  11. Ilie, M., et al. Use of the 22C3 anti-programmed death ligand 1 antibody to determine programmed death ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. Cancer Cytopathology. 126 (4), 264-274 (2018).
  12. Skov, B. G., Skov, T. Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Applied Immunohistochemistry & Molecular Morphology. 25 (7), 453-459 (2017).
  13. Russell-Goldman, E., Kravets, S., Dahlberg, S. E., Sholl, L. M., Vivero, M. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathology. 126 (4), 253-263 (2018).
  14. Heymann, J. J., et al. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathology. 125 (12), 896-907 (2017).
  15. Stoy, S. P., Rosen, L., Mueller, J., Murgu, S. Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy. Cancer Cytopathology. 126 (2), 122-128 (2018).
  16. Ilie, M., Hofman, P. Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them. Translational Lung Cancer Research. 6 (Suppl 1), S51-S54 (2017).

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved